박병탁 기자

Park Pyeongtak

Reporter
Biowatch Team With a background in Business Administration (MBA), I focus on the pharmaceutical and biotech industries. My goal is to select key information and present it in an easily understandable manner.
mail ppt@kormedi.com

Latest Articles

‘Singapore Is the Bridge, Not the Destination’: Novo Holdings Connects Asian Biotech to Global Capital

Celltrion Files Phase 4 IND with FDA to Support 240 mg High-Dose Zymfentra Regimen in US

Celltrion Targets 33% Shareholder Payout Ratio, Adds 100 Billion Won Share Buyback

Samsung Biologics to Raise ₩3 Trillion in Rights Offering to Fund ₩2.7 Trillion Acquisition of PolyPeptide Group

Celltrion to Select Japanese Biotech Startups for Joint R&D and Pipeline Expansion

Kyungdong Pharmaceutical and AUL Bio Seek Phase 1 Approval for Once-Monthly Obesity Drug AUL009

South Korea’s First Homegrown CAR-T, Rimqarto, Moves Closer to Coverage with 67% Complete Response Rate

SK Plasma Launches High-Dose Revolpag 75 mg to Simplify Thrombocytopenia Regimens and Cut Costs

Previous12345Next